The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.
Using 10x Genomics' immune profiling and ATAC-seq assays, the researchers upended the notion that cancer-fighting T cells come from within a tumor.
An op-ed in the Washington Post calls for peer review to not be used as a 'gold standard' and for its limitations to be more widely known.
Three medical writing organizations warn about the harm predatory journals could do to the scientific literature.
Researchers at Harvard, Peking University, and Yikon Genomics suggested that their noninvasive test is more specific than the prevailing biopsy-based method.
The Washington Post reports that US Department of Agriculture researchers will no longer have to label their peer-reviewed articles as "preliminary."
Though the test is already commercially available, the firm met with the FDA last year to discuss plans for a randomized controlled trial to support regulatory approval.
MSK researchers showed that high TMB may be associated with improved survival across tumor types, but the cut-offs for high and low status will vary based on histology.
Data from the GUIDED study will be central to commercial payor discussions, a Medicare LCD reconsideration request, and eventually expansion into the primary care market.
The investment bank upgraded the company's stock to an Outperform rating from Market Perform but lowered its price target to $37 per share.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.